Hundreds Of Alzheimer’s Drugs Targeting Amyloids Have Crashed And Burned. Why Is Pharma Still Obsessed With Them?
Blog
Drug after drug after drug that targeted a brain compound called beta amyloid have failed over the years. “We are running out of excuses” for why beta-amyloid treatments aren’t working, said Zaven Khachaturian, editor-in-chief of the medical journal Alzheimer’s & Dementia. But drugmakers “keep trying, hoping that the path they are on is going to give blockbuster drugs.”
Recent Posts
T-Neuro Pharma Welcomes Renowned Alzheimer’s Researcher Dr. Jeffrey Cummings as Chair of Scientific Advisory Board
By
tn3ur0pharma
CHICAGO STAR: T-Neuro Pharma to Presents Expanded Alzheimer’s Disease Blood Biomarker Assay at Clinical Trials on Alzheimer’s Disease (CTAD) conference
By
tn3ur0pharma
BIOSPACE: T-Neuro Pharma’s Trailblazing Alzheimer’s Research Receives Acclaim in PNAS Commentary
By
tn3ur0pharma